{
    "abstract": "Background: Typhoid fever remains a major public health problem in low- and middle-income countries where children aged 2\u201314 years bear the greatest burden. Vi polysaccharide is poorly immunogenic in children <2 years of age, and protection in adults is modest. The limitations of Vi polysaccharide vaccines can be overcome by conjugation of the Vi to a carrier protein. A typhoid conjugate vaccine composed of Vi polysaccharide conjugated to diphtheria toxoid (Vi-DT) has been developed. The Phase I study results are presented here. Methods: This was a randomized, observer-blinded Phase I study to assess the safety and immunogenicity of Vi-DT compared to Vi polysaccharide vaccine, conducted in Manila, Philippines. Participants enrolled in an age de-escalation manner (18\u201345, 6\u201317 and 2\u20135 years) were randomized between Test (Vi-DT, 25 \u00b5g) administered at 0 and 4 weeks and Comparator (Vi polysaccharide, Typhim Vi\u00ae and Vaxigrip\u00ae Sanofi Pasteur) vaccines. Results: A total of 144 participants were enrolled (48 by age strata, 24 in Test and Comparator groups each). No serious adverse event was reported in either group. Solicited and unsolicited adverse events were mild or moderate in both groups with the exception of a 4-year old girl in Test group with grade 3 fever which resolved without sequelae. All participants in Test group seroconverted after first and second doses of Vi-DT while the proportions in the Comparator group were 97.1% and 97.2%, after first dose of Typhim Vi\u00ae and second dose of Vaxigrip\u00ae respectively. Vi-DT showed 4-fold higher Geometric Mean Titers (GMT) compared to Typhim Vi\u00ae (adjusted for age strata, p < 0.001). No further increase of GMT was detected after the second dose of Vi-DT. Anti-DT IgG seroresponse rates were 81.2% and 84.5% post first and second Vi-DT doses, respectively. Conclusions: Vi-DT vaccine was safe, well-tolerated and immunogenic in participants aged 2\u201345 years. ClinicalTrials.gov registration number: NCT02645032.",
    "author_highlights": [
        {
            "endOffset": 10406,
            "sentence": "Vi-DT is safe and well tolerated in participants aged 2\u201345 years.",
            "startOffset": 10341
        },
        {
            "endOffset": 10494,
            "sentence": "Significantly higher immune responses post Vi-DT compared to Vi polysaccharide vaccine.",
            "startOffset": 10407
        },
        {
            "endOffset": 10579,
            "sentence": "No further increase in GMT post second dose as compared to post first dose of Vi-DT.",
            "startOffset": 10495
        }
    ],
    "bib_entries": {
        "b0005": null,
        "b0010": {
            "authors": [
                {
                    "first": "Marina",
                    "initial": "M.",
                    "last": "Antill\u00f3n"
                },
                {
                    "first": "Joke",
                    "initial": "J.",
                    "last": "Bilcke"
                },
                {
                    "first": "A. David",
                    "initial": "A.D.",
                    "last": "Paltiel"
                },
                {
                    "first": "Virginia E.",
                    "initial": "V.E.",
                    "last": "Pitzer"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.05.001",
            "firstpage": "3506",
            "issn": "0264410X",
            "lastpage": "3514",
            "pmid": "28527687",
            "pub_year": 2017,
            "title": "Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings",
            "volume": "35"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Zulfiqar Ahmed",
                    "initial": "Z.A.",
                    "last": "Bhutta"
                }
            ],
            "doi": "10.1136/adc.75.3.214",
            "firstpage": "214",
            "issn": "00039888",
            "lastpage": "217",
            "pub_year": 1996,
            "title": "Impact of age and drug resistance on mortality in typhoid fever",
            "volume": "75"
        },
        "b0020": null,
        "b0025": {
            "authors": [
                {
                    "first": "M. K.",
                    "initial": "M.K.",
                    "last": "Bhan"
                },
                {
                    "first": "Rajiv",
                    "initial": "R.",
                    "last": "Bahl"
                },
                {
                    "first": "Shinjini",
                    "initial": "S.",
                    "last": "Bhatnagar"
                }
            ],
            "doi": "10.1016/S0140-6736(05)67181-4",
            "firstpage": "749",
            "issn": "01406736",
            "lastpage": "762",
            "pmid": "16125594",
            "pub_year": 2005,
            "title": "Typhoid and paratyphoid fever",
            "volume": "366"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Rumina",
                    "initial": "R.",
                    "last": "Hasan"
                },
                {
                    "first": "Afia",
                    "initial": "A.",
                    "last": "Zafar"
                },
                {
                    "first": "Zohair",
                    "initial": "Z.",
                    "last": "Abbas"
                },
                {
                    "first": "Vikram",
                    "initial": "V.",
                    "last": "Mahraj"
                },
                {
                    "first": "Faisal",
                    "initial": "F.",
                    "last": "Malik"
                },
                {
                    "first": "Anita",
                    "initial": "A.",
                    "last": "Zaidi"
                }
            ],
            "firstpage": "289",
            "issn": "19722680",
            "lastpage": "294",
            "pmid": "19741291",
            "pub_year": 2008,
            "title": "Antibiotic resistance among Salmonella enterica serovars Typhi and Paratyphi A in Pakistan (2001-2006).",
            "volume": "2"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Rose A.",
                    "initial": "R.A.",
                    "last": "Rudd"
                },
                {
                    "first": "Len J.",
                    "initial": "L.J.",
                    "last": "Paulozzi"
                },
                {
                    "first": "Michael J.",
                    "initial": "M.J.",
                    "last": "Bauer"
                },
                {
                    "first": "Richard W.",
                    "initial": "R.W.",
                    "last": "Burleson"
                },
                {
                    "first": "Rick E.",
                    "initial": "R.E.",
                    "last": "Carlson"
                },
                {
                    "first": "Dan",
                    "initial": "D.",
                    "last": "Dao"
                },
                {
                    "first": "James W.",
                    "initial": "J.W.",
                    "last": "Davis"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Dudek"
                },
                {
                    "first": "Beth Ann",
                    "initial": "B.A.",
                    "last": "Eichler"
                },
                {
                    "first": "Jessie C.",
                    "initial": "J.C.",
                    "last": "Fernandes"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Fondario"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Gabella"
                },
                {
                    "first": "Beth",
                    "initial": "B.",
                    "last": "Hume"
                },
                {
                    "first": "Theron",
                    "initial": "T.",
                    "last": "Huntamer"
                },
                {
                    "first": "Mbabazi",
                    "initial": "M.",
                    "last": "Kariisa"
                },
                {
                    "first": "Thomas W.",
                    "initial": "T.W.",
                    "last": "Largo"
                },
                {
                    "first": "Jo Anne",
                    "initial": "J.A.",
                    "last": "Miles"
                },
                {
                    "first": "Ashley",
                    "initial": "A.",
                    "last": "Newmyer"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Nitcheva"
                },
                {
                    "first": "Beatriz E.",
                    "initial": "B.E.",
                    "last": "Perez"
                },
                {
                    "first": "Scott K.",
                    "initial": "S.K.",
                    "last": "Proescholdbell"
                },
                {
                    "first": "Jennifer C.",
                    "initial": "J.C.",
                    "last": "Sabel"
                },
                {
                    "first": "Jessica",
                    "initial": "J.",
                    "last": "Skiba"
                },
                {
                    "first": "Svetla",
                    "initial": "S.",
                    "last": "Slavova"
                },
                {
                    "first": "Kathy",
                    "initial": "K.",
                    "last": "Stone"
                },
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "Tharp"
                },
                {
                    "first": "Tracy",
                    "initial": "T.",
                    "last": "Wendling"
                },
                {
                    "first": "Dagan",
                    "initial": "D.",
                    "last": "Wright"
                },
                {
                    "first": "Anne M.",
                    "initial": "A.M.",
                    "last": "Zehner"
                }
            ],
            "firstpage": "849",
            "issn": "01492195",
            "lastpage": "854",
            "pmid": "25275328",
            "pub_year": 2014,
            "title": "Increases in heroin overdose deaths \u2014 28 states, 2010 to 2012",
            "volume": "63"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Rachael",
                    "initial": "R.",
                    "last": "Milligan"
                },
                {
                    "first": "Mical",
                    "initial": "M.",
                    "last": "Paul"
                },
                {
                    "first": "Marty",
                    "initial": "M.",
                    "last": "Richardson"
                },
                {
                    "first": "Ami",
                    "initial": "A.",
                    "last": "Neuberger"
                }
            ],
            "doi": "10.1002/14651858.CD001261.pub4",
            "issn": "1469493X",
            "pmid": "29851031",
            "pub_year": 2018,
            "title": "Vaccines for preventing typhoid fever",
            "volume": "2018"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "Robert E.",
                    "initial": "R.E.",
                    "last": "Black"
                },
                {
                    "first": "Catterine",
                    "initial": "C.",
                    "last": "Ferreccio"
                },
                {
                    "first": "Rene",
                    "initial": "R.",
                    "last": "Germanier"
                }
            ],
            "doi": "10.1016/S0140-6736(87)90480-6",
            "firstpage": "1049",
            "issn": "01406736",
            "lastpage": "1052",
            "pmid": "2883393",
            "pub_year": 1987,
            "title": "LARGE-SCALE FIELD TRIAL OF TY21A LIVE ORAL TYPHOID VACCINE IN ENTERIC-COATED CAPSULE FORMULATION",
            "volume": "329"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "Catterine",
                    "initial": "C.",
                    "last": "Ferreccio"
                },
                {
                    "first": "Paulina",
                    "initial": "P.",
                    "last": "Abrego"
                },
                {
                    "first": "Oriana San",
                    "initial": "O.S.",
                    "last": "Martin"
                },
                {
                    "first": "Edith",
                    "initial": "E.",
                    "last": "Ortiz"
                },
                {
                    "first": "Stanley",
                    "initial": "S.",
                    "last": "Cryz"
                }
            ],
            "doi": "10.1016/S0264-410X(99)00231-5",
            "firstpage": "S22",
            "issn": "0264410X",
            "lastpage": "S27",
            "pmid": "10506405",
            "pub_year": 1999,
            "title": "Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine",
            "volume": "17"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Keith P.",
                    "initial": "K.P.",
                    "last": "Klugman"
                },
                {
                    "first": "Hendrik J.",
                    "initial": "H.J.",
                    "last": "Koornhof"
                },
                {
                    "first": "John B.",
                    "initial": "J.B.",
                    "last": "Robbins"
                },
                {
                    "first": "Nancy N.",
                    "initial": "N.N.",
                    "last": "Le Cam"
                }
            ],
            "doi": "10.1016/0264-410X(95)00186-5",
            "firstpage": "435",
            "issn": "0264410X",
            "lastpage": "438",
            "pmid": "8735556",
            "pub_year": 1996,
            "title": "Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization",
            "volume": "14"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Elspeth",
                    "initial": "E.",
                    "last": "Anwar"
                },
                {
                    "first": "Elad",
                    "initial": "E.",
                    "last": "Goldberg"
                },
                {
                    "first": "Abigail",
                    "initial": "A.",
                    "last": "Fraser"
                },
                {
                    "first": "Camilo J.",
                    "initial": "C.J.",
                    "last": "Acosta"
                },
                {
                    "first": "Mical",
                    "initial": "M.",
                    "last": "Paul"
                },
                {
                    "first": "Leonard",
                    "initial": "L.",
                    "last": "Leibovici"
                }
            ],
            "doi": "10.1002/14651858.CD001261.pub3",
            "issn": "1469493X",
            "pmid": "24385413",
            "pub_year": 2014,
            "title": "Vaccines for preventing typhoid fever",
            "volume": "2014"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Cadoz"
                }
            ],
            "doi": "10.1016/S0264-410X(98)00097-8",
            "firstpage": "1391",
            "issn": "0264410X",
            "lastpage": "1395",
            "pmid": "9711777",
            "pub_year": 1998,
            "title": "Potential and limitations of polysaccharide vaccines in infancy",
            "volume": "16"
        },
        "b0070": null,
        "b0075": {
            "authors": [
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Jakobsen"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Jonsdottir"
                }
            ],
            "doi": "10.1046/j.1365-3083.2003.01292.x",
            "firstpage": "119",
            "issn": "03009475",
            "lastpage": "128",
            "pmid": "12869132",
            "pub_year": 2003,
            "title": "Mucosal vaccination against encapsulated respiratory bacteria - New potentials for conjugate vaccines?",
            "volume": "58"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Shousun Chen",
                    "initial": "S.C.",
                    "last": "Szu"
                }
            ],
            "doi": "10.1586/14760584.2013.845529",
            "firstpage": "1273",
            "issn": "14760584",
            "lastpage": "1286",
            "pmid": "24156285",
            "pub_year": 2013,
            "title": "Development of Vi conjugate - A new generation of typhoid vaccine",
            "volume": "12"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Vu Dinh",
                    "initial": "V.D.",
                    "last": "Thiem"
                },
                {
                    "first": "Feng Ying C.",
                    "initial": "F.Y.C.",
                    "last": "Lin"
                },
                {
                    "first": "Do Gia",
                    "initial": "D.G.",
                    "last": "Canh"
                },
                {
                    "first": "Nguyen Hong",
                    "initial": "N.H.",
                    "last": "Son"
                },
                {
                    "first": "Dang Duc",
                    "initial": "D.D.",
                    "last": "Anh"
                },
                {
                    "first": "Nguyen Duc",
                    "initial": "N.D.",
                    "last": "Mao"
                },
                {
                    "first": "Chiayung",
                    "initial": "C.",
                    "last": "Chu"
                },
                {
                    "first": "Steven W.",
                    "initial": "S.W.",
                    "last": "Hunt"
                },
                {
                    "first": "John B.",
                    "initial": "J.B.",
                    "last": "Robbins"
                },
                {
                    "first": "Rachel",
                    "initial": "R.",
                    "last": "Schneerson"
                },
                {
                    "first": "Shousun C.",
                    "initial": "S.C.",
                    "last": "Szu"
                }
            ],
            "doi": "10.1128/CVI.00532-10",
            "firstpage": "730",
            "issn": "15566811",
            "lastpage": "735",
            "pmid": "21411598",
            "pub_year": 2011,
            "title": "The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines",
            "volume": "18"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Ligia M.",
                    "initial": "L.M.",
                    "last": "Cruz Espinoza"
                },
                {
                    "first": "Chelsea",
                    "initial": "C.",
                    "last": "Nichols"
                },
                {
                    "first": "Yaw",
                    "initial": "Y.",
                    "last": "Adu-Sarkodie"
                },
                {
                    "first": "Hassan M.",
                    "initial": "H.M.",
                    "last": "Al-Emran"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Baker"
                },
                {
                    "first": "John D.",
                    "initial": "J.D.",
                    "last": "Clemens"
                },
                {
                    "first": "Denise Myriam",
                    "initial": "D.M.",
                    "last": "Dekker"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Eibach"
                },
                {
                    "first": "Ralf",
                    "initial": "R.",
                    "last": "Krumkamp"
                },
                {
                    "first": "Kennedy",
                    "initial": "K.",
                    "last": "Boahen"
                },
                {
                    "first": "Justin",
                    "initial": "J.",
                    "last": "Im"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Jaeger"
                },
                {
                    "first": "Vera",
                    "initial": "V.",
                    "last": "Von Kalckreuth"
                },
                {
                    "first": "Gi Deok",
                    "initial": "G.D.",
                    "last": "Pak"
                },
                {
                    "first": "Ursula",
                    "initial": "U.",
                    "last": "Panzner"
                },
                {
                    "first": "Se Eun",
                    "initial": "S.E.",
                    "last": "Park"
                },
                {
                    "first": "Jin Kyung",
                    "initial": "J.K.",
                    "last": "Park"
                },
                {
                    "first": "Nimako",
                    "initial": "N.",
                    "last": "Sarpong"
                },
                {
                    "first": "Heidi",
                    "initial": "H.",
                    "last": "Sch\u00fctt-Gerowitt"
                },
                {
                    "first": "Trevor",
                    "initial": "T.",
                    "last": "Toy"
                },
                {
                    "first": "Thomas F.",
                    "initial": "T.F.",
                    "last": "Wierzba"
                },
                {
                    "first": "Florian",
                    "initial": "F.",
                    "last": "Marks"
                },
                {
                    "first": "J\u00fcrgen",
                    "initial": "J.",
                    "last": "May"
                }
            ],
            "doi": "10.1093/cid/civ787",
            "firstpage": "s17",
            "issn": "10584838",
            "lastpage": "s22",
            "pmid": "26933015",
            "pub_year": 2016,
            "title": "Variations of Invasive Salmonella Infections by Population Size in Asante Akim North Municipal, Ghana",
            "volume": "62"
        },
        "b0095": {
            "authors": [
                {
                    "first": "W. Abdullah",
                    "initial": "W.A.",
                    "last": "Brooks"
                },
                {
                    "first": "Anowar",
                    "initial": "A.",
                    "last": "Hossain"
                },
                {
                    "first": "Doli",
                    "initial": "D.",
                    "last": "Goswami"
                },
                {
                    "first": "Amina Tahia",
                    "initial": "A.T.",
                    "last": "Sharmeen"
                },
                {
                    "first": "Kamrun",
                    "initial": "K.",
                    "last": "Nahar"
                },
                {
                    "first": "Khorshed",
                    "initial": "K.",
                    "last": "Alam"
                },
                {
                    "first": "Noor",
                    "initial": "N.",
                    "last": "Ahmed"
                },
                {
                    "first": "Aliya",
                    "initial": "A.",
                    "last": "Naheed"
                },
                {
                    "first": "G. Balakrish",
                    "initial": "G.B.",
                    "last": "Nair"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Luby"
                },
                {
                    "first": "Robert F.",
                    "initial": "R.F.",
                    "last": "Breiman"
                }
            ],
            "doi": "10.3201/eid1102.040422",
            "firstpage": "326",
            "issn": "10806040",
            "lastpage": "329",
            "pmid": "15752457",
            "pub_year": 2005,
            "title": "Bacteremic typhoid fever in children in an urban slum, Bangladesh",
            "volume": "11"
        },
        "b0100": null,
        "b0105": {
            "authors": [
                {
                    "first": "Shousun C.",
                    "initial": "S.C.",
                    "last": "Szu"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Hunt"
                },
                {
                    "first": "Guilin",
                    "initial": "G.",
                    "last": "Xie"
                },
                {
                    "first": "John B.",
                    "initial": "J.B.",
                    "last": "Robbins"
                },
                {
                    "first": "Rachel",
                    "initial": "R.",
                    "last": "Schneerson"
                },
                {
                    "first": "Rajesh K.",
                    "initial": "R.K.",
                    "last": "Gupta"
                },
                {
                    "first": "Zhigang",
                    "initial": "Z.",
                    "last": "Zhao"
                },
                {
                    "first": "Xiaomei",
                    "initial": "X.",
                    "last": "Tan"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.02.006",
            "firstpage": "1970",
            "issn": "0264410X",
            "lastpage": "1974",
            "pmid": "23422143",
            "pub_year": 2013,
            "title": "A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned",
            "volume": "31"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Mi Seon",
                    "initial": "M.S.",
                    "last": "Jang"
                },
                {
                    "first": "Sushant",
                    "initial": "S.",
                    "last": "Sahastrabuddhe"
                },
                {
                    "first": "Cheol Heui",
                    "initial": "C.H.",
                    "last": "Yun"
                },
                {
                    "first": "Seung Hyun",
                    "initial": "S.H.",
                    "last": "Han"
                },
                {
                    "first": "Jae Seung",
                    "initial": "J.S.",
                    "last": "Yang"
                }
            ],
            "doi": "10.1016/j.micpath.2016.05.013",
            "firstpage": "19",
            "issn": "08824010",
            "lastpage": "26",
            "pmid": "27216239",
            "pub_year": 2016,
            "title": "Serum bactericidal assay for the evaluation of typhoid vaccine using a semi-automated colony-counting method",
            "volume": "97"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Monjori",
                    "initial": "M.",
                    "last": "Mitra"
                },
                {
                    "first": "Nitin",
                    "initial": "N.",
                    "last": "Shah"
                },
                {
                    "first": "Apurba",
                    "initial": "A.",
                    "last": "Ghosh"
                },
                {
                    "first": "Suparna",
                    "initial": "S.",
                    "last": "Chatterjee"
                },
                {
                    "first": "Iqbal",
                    "initial": "I.",
                    "last": "Kaur"
                },
                {
                    "first": "Nisha",
                    "initial": "N.",
                    "last": "Bhattacharya"
                },
                {
                    "first": "Suparna",
                    "initial": "S.",
                    "last": "Basu"
                }
            ],
            "doi": "10.1080/21645515.2015.1117715",
            "firstpage": "939",
            "issn": "21645515",
            "lastpage": "945",
            "pmid": "26901576",
            "pub_year": 2016,
            "title": "Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph\u2122) in Indian children: School based cluster randomized study",
            "volume": "12"
        },
        "b0120": {
            "authors": [
                {
                    "first": "So Jung",
                    "initial": "S.J.",
                    "last": "An"
                },
                {
                    "first": "Yeon Kyung",
                    "initial": "Y.K.",
                    "last": "Yoon"
                },
                {
                    "first": "Sudeep",
                    "initial": "S.",
                    "last": "Kothari"
                },
                {
                    "first": "Deok Ryun",
                    "initial": "D.R.",
                    "last": "Kim"
                },
                {
                    "first": "Jeong Ah",
                    "initial": "J.A.",
                    "last": "Kim"
                },
                {
                    "first": "Neha",
                    "initial": "N.",
                    "last": "Kothari"
                },
                {
                    "first": "Eugene",
                    "initial": "E.",
                    "last": "Lee"
                },
                {
                    "first": "Tai Hyun",
                    "initial": "T.H.",
                    "last": "Park"
                },
                {
                    "first": "Rodney",
                    "initial": "R.",
                    "last": "Carbis"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.12.046",
            "firstpage": "1023",
            "issn": "0264410X",
            "lastpage": "1028",
            "pmid": "22192846",
            "pub_year": 2012,
            "title": "Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine",
            "volume": "30"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "van Damme"
                },
                {
                    "first": "Froukje",
                    "initial": "F.",
                    "last": "Kafeja"
                },
                {
                    "first": "Alessandra",
                    "initial": "A.",
                    "last": "Anemona"
                },
                {
                    "first": "Venere",
                    "initial": "V.",
                    "last": "Basile"
                },
                {
                    "first": "Anne Katrin",
                    "initial": "A.K.",
                    "last": "Hilbert"
                },
                {
                    "first": "Ilse",
                    "initial": "I.",
                    "last": "de Coster"
                },
                {
                    "first": "Simona",
                    "initial": "S.",
                    "last": "Rondini"
                },
                {
                    "first": "Francesca",
                    "initial": "F.",
                    "last": "Micoli"
                },
                {
                    "first": "Rana M.",
                    "initial": "R.M.",
                    "last": "Khan"
                },
                {
                    "first": "Elisa",
                    "initial": "E.",
                    "last": "Marchetti"
                },
                {
                    "first": "Vito",
                    "initial": "V.",
                    "last": "Di Cioccio"
                },
                {
                    "first": "Allan",
                    "initial": "A.",
                    "last": "Saul"
                },
                {
                    "first": "Laura B.",
                    "initial": "L.B.",
                    "last": "Martin"
                },
                {
                    "first": "Audino",
                    "initial": "A.",
                    "last": "Podda"
                }
            ],
            "doi": "10.1371/journal.pone.0025398",
            "issn": "19326203",
            "pmid": "21980445",
            "pub_year": 2011,
            "title": "Safety, immunogenicity and dose ranging of a new VI-CRM 197 conjugate vaccine against typhoid fever: Randomized clinical testing in healthy adults",
            "volume": "6"
        },
        "b0130": null,
        "b0135": {
            "authors": [
                {
                    "first": "Do Gia",
                    "initial": "D.G.",
                    "last": "Canh"
                },
                {
                    "first": "Feng Ying",
                    "initial": "F.Y.",
                    "last": "Lin"
                },
                {
                    "first": "Vu Dinh",
                    "initial": "V.D.",
                    "last": "Thiem"
                },
                {
                    "first": "Dang Due",
                    "initial": "D.D.",
                    "last": "Trach"
                },
                {
                    "first": "Nguyen Dinh",
                    "initial": "N.D.",
                    "last": "Trong"
                },
                {
                    "first": "Nguyen Due",
                    "initial": "N.D.",
                    "last": "Mao"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Hunt"
                },
                {
                    "first": "Rachel",
                    "initial": "R.",
                    "last": "Schneerson"
                },
                {
                    "first": "John B.",
                    "initial": "J.B.",
                    "last": "Robbins"
                },
                {
                    "first": "Chiayung",
                    "initial": "C.",
                    "last": "Chu"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Shiloach"
                },
                {
                    "first": "Dolores A.",
                    "initial": "D.A.",
                    "last": "Bryla"
                },
                {
                    "first": "Marie Claude",
                    "initial": "M.C.",
                    "last": "Bonnet"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Schulz"
                },
                {
                    "first": "Shousun C.",
                    "initial": "S.C.",
                    "last": "Szu"
                }
            ],
            "doi": "10.1128/IAI.72.11.6586-6588.2004",
            "firstpage": "6586",
            "issn": "00199567",
            "lastpage": "6588",
            "pmid": "15501790",
            "pub_year": 2004,
            "title": "Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children",
            "volume": "72"
        },
        "b0140": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Tontini"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Berti"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Romano"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Proietti"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Zambonelli"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Bottomley"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "De Gregorio"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Del Giudice"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Rappuoli"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Costantino"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.07.078",
            "firstpage": "4827",
            "issn": "0264410X",
            "lastpage": "4833",
            "pmid": "23965218",
            "pub_year": 2013,
            "title": "Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines",
            "volume": "31"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Vadrevu Krishna",
                    "initial": "V.K.",
                    "last": "Mohan"
                },
                {
                    "first": "Vineeth",
                    "initial": "V.",
                    "last": "Varanasi"
                },
                {
                    "first": "Anit",
                    "initial": "A.",
                    "last": "Singh"
                },
                {
                    "first": "Marcela F.",
                    "initial": "M.F.",
                    "last": "Pasetti"
                },
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "Ramasamy",
                    "initial": "R.",
                    "last": "Venkatesan"
                },
                {
                    "first": "Krishna M.",
                    "initial": "K.M.",
                    "last": "Ella"
                }
            ],
            "doi": "10.1093/cid/civ295",
            "firstpage": "393",
            "issn": "10584838",
            "lastpage": "402",
            "pmid": "25870324",
            "pub_year": 2015,
            "title": "Safety and Immunogenicity of a Vi Polysaccharide-Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study",
            "volume": "61"
        },
        "b0150": {
            "authors": [
                {
                    "first": "John D.",
                    "initial": "J.D.",
                    "last": "Clemens"
                },
                {
                    "first": "Bonita F.",
                    "initial": "B.F.",
                    "last": "Stanton"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Chakraborty"
                },
                {
                    "first": "David A.",
                    "initial": "D.A.",
                    "last": "Sack"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Khan"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Huda"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Ahmed"
                },
                {
                    "first": "Jeffrey R.",
                    "initial": "J.R.",
                    "last": "Harris"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Yunus"
                },
                {
                    "first": "M. U.",
                    "initial": "M.U.",
                    "last": "Khan"
                },
                {
                    "first": "Ann Mari",
                    "initial": "A.M.",
                    "last": "Svennerholm"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Jertborn"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Holmgren"
                }
            ],
            "doi": "10.1093/infdis/155.1.79",
            "firstpage": "79",
            "issn": "00221899",
            "lastpage": "85",
            "pmid": "3540139",
            "pub_year": 1987,
            "title": "B Subunit-Whole Cell and Whole Cell-Only Oral Vaccines Against Cholera: Studies on Reactogenicity and Immunogenicity",
            "volume": "155"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Susan E.",
                    "initial": "S.E.",
                    "last": "Maslanka"
                },
                {
                    "first": "Linda L.",
                    "initial": "L.L.",
                    "last": "Gheesling"
                },
                {
                    "first": "Daniel E.",
                    "initial": "D.E.",
                    "last": "Libutti"
                },
                {
                    "first": "Kimberley B.J.",
                    "initial": "K.B.J.",
                    "last": "Donaldson"
                },
                {
                    "first": "Hani S.",
                    "initial": "H.S.",
                    "last": "Harakeh"
                },
                {
                    "first": "Janet K.",
                    "initial": "J.K.",
                    "last": "Dykes"
                },
                {
                    "first": "Francis F.",
                    "initial": "F.F.",
                    "last": "Arhin"
                },
                {
                    "first": "Sarvamangala J.N.",
                    "initial": "S.J.N.",
                    "last": "Devi"
                },
                {
                    "first": "Carl E.",
                    "initial": "C.E.",
                    "last": "Frasch"
                },
                {
                    "first": "Jay C.",
                    "initial": "J.C.",
                    "last": "Huang"
                },
                {
                    "first": "Paula",
                    "initial": "P.",
                    "last": "Kriz-Kuzemenska"
                },
                {
                    "first": "Robert D.",
                    "initial": "R.D.",
                    "last": "Lemmon"
                },
                {
                    "first": "Manon",
                    "initial": "M.",
                    "last": "Lorange"
                },
                {
                    "first": "Carla C.A.M.",
                    "initial": "C.C.A.M.",
                    "last": "Peeters"
                },
                {
                    "first": "Sally",
                    "initial": "S.",
                    "last": "Quataert"
                },
                {
                    "first": "Joseph Y.",
                    "initial": "J.Y.",
                    "last": "Tai"
                },
                {
                    "first": "George M.",
                    "initial": "G.M.",
                    "last": "Carlone"
                },
                {
                    "first": "Elaine L.",
                    "initial": "E.L.",
                    "last": "Mills"
                },
                {
                    "first": "Fraser E.",
                    "initial": "F.E.",
                    "last": "Ashton"
                },
                {
                    "first": "Jacob",
                    "initial": "J.",
                    "last": "Diepevaen"
                },
                {
                    "first": "Joanna",
                    "initial": "J.",
                    "last": "Bielecki"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Bybel"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Cloutier"
                },
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                }
            ],
            "firstpage": "156",
            "issn": "1071412X",
            "lastpage": "167",
            "pmid": "9067649",
            "pub_year": 1997,
            "title": "Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays",
            "volume": "4"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Anoop S.",
                    "initial": "A.S.",
                    "last": "Pulickal"
                },
                {
                    "first": "Samir",
                    "initial": "S.",
                    "last": "Gautam"
                },
                {
                    "first": "Elizabeth A.",
                    "initial": "E.A.",
                    "last": "Clutterbuck"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Thorson"
                },
                {
                    "first": "Buddha",
                    "initial": "B.",
                    "last": "Basynat"
                },
                {
                    "first": "Neelam",
                    "initial": "N.",
                    "last": "Adhikari"
                },
                {
                    "first": "Katherine",
                    "initial": "K.",
                    "last": "Makepeace"
                },
                {
                    "first": "Sjoerd",
                    "initial": "S.",
                    "last": "Rijpkema"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Jeremy J.",
                    "initial": "J.J.",
                    "last": "Farrar"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1128/CVI.00245-09",
            "firstpage": "1413",
            "issn": "15566811",
            "lastpage": "1419",
            "pmid": "19710294",
            "pub_year": 2009,
            "title": "Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal",
            "volume": "16"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Anu",
                    "initial": "A.",
                    "last": "Kantele"
                },
                {
                    "first": "Sari H.",
                    "initial": "S.H.",
                    "last": "Pakkanen"
                },
                {
                    "first": "Riitta",
                    "initial": "R.",
                    "last": "Karttunen"
                },
                {
                    "first": "Jussi M.",
                    "initial": "J.M.",
                    "last": "Kantele"
                }
            ],
            "doi": "10.1371/journal.pone.0060583",
            "issn": "19326203",
            "pmid": "23593253",
            "pub_year": 2013,
            "title": "Head-to-Head Comparison of Humoral Immune Responses to Vi Capsular Polysaccharide and Salmonella Typhi Ty21a Typhoid Vaccines-A Randomized Trial",
            "volume": "8"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Nicholas A.",
                    "initial": "N.A.",
                    "last": "Feasey"
                },
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                }
            ],
            "doi": "10.1016/S0140-6736(17)32407-8",
            "firstpage": "2419",
            "issn": "01406736",
            "lastpage": "2421",
            "pmid": "28965714",
            "pub_year": 2017,
            "title": "Typhoid vaccine development with a human challenge model",
            "volume": "390"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Darton"
                },
                {
                    "first": "Claire",
                    "initial": "C.",
                    "last": "Jones"
                },
                {
                    "first": "Christoph J.",
                    "initial": "C.J.",
                    "last": "Blohmke"
                },
                {
                    "first": "Claire S.",
                    "initial": "C.S.",
                    "last": "Waddington"
                },
                {
                    "first": "Liqing",
                    "initial": "L.",
                    "last": "Zhou"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Peters"
                },
                {
                    "first": "Kathryn",
                    "initial": "K.",
                    "last": "Haworth"
                },
                {
                    "first": "Rebecca",
                    "initial": "R.",
                    "last": "Sie"
                },
                {
                    "first": "Christopher A.",
                    "initial": "C.A.",
                    "last": "Green"
                },
                {
                    "first": "Catherine A.",
                    "initial": "C.A.",
                    "last": "Jeppesen"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Moore"
                },
                {
                    "first": "Ben A.V.",
                    "initial": "B.A.V.",
                    "last": "Thompson"
                },
                {
                    "first": "Tessa",
                    "initial": "T.",
                    "last": "John"
                },
                {
                    "first": "Robert A.",
                    "initial": "R.A.",
                    "last": "Kingsley"
                },
                {
                    "first": "Ly Mee",
                    "initial": "L.M.",
                    "last": "Yu"
                },
                {
                    "first": "Merryn",
                    "initial": "M.",
                    "last": "Voysey"
                },
                {
                    "first": "Zoe",
                    "initial": "Z.",
                    "last": "Hindle"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Lockhart"
                },
                {
                    "first": "Marcelo B.",
                    "initial": "M.B.",
                    "last": "Sztein"
                },
                {
                    "first": "Gordon",
                    "initial": "G.",
                    "last": "Dougan"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Angus"
                },
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1371/journal.pntd.0004926",
            "issn": "19352727",
            "pmid": "27533046",
            "pub_year": 2016,
            "title": "Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a",
            "volume": "10"
        },
        "b0180": null
    },
    "body_text": [
        {
            "endOffset": 22441,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The randomization lists contained sequential numbers unique to each participant in each age group.",
            "startOffset": 22343,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 32432,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 32431,
                    "startOffset": 32427
                }
            },
            "secId": "s0065",
            "sentence": "In a Phase I study testing Vi-CRM197 in European adults, anti-Vi IgG GMT levels four weeks post vaccination were six times higher than those vaccinated with Vi alone (304 vs. 52 EU/mL) [24].",
            "startOffset": 32242,
            "title": "Discussion"
        },
        {
            "endOffset": 24023,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The comparison of proportions for all ages was performed using stratified Chi-square (Cochran-Mantel-Haenszel) test stratified by age, and the comparison in each age cohort was performed using Pearson\u2019s Chi-square test or Fisher\u2019s Exact test.",
            "startOffset": 23781,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 20528,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "In the age de-escalating procedure, blinded safety data of the older cohort was reviewed by an independent Safety Monitoring Committee (SMC).",
            "startOffset": 20387,
            "title": "Assessment of safety and reactogenicity"
        },
        {
            "endOffset": 31011,
            "parents": [],
            "secId": "s0065",
            "sentence": "Test group showed about 4-fold higher GMT compared to Comparator group.",
            "startOffset": 30940,
            "title": "Discussion"
        },
        {
            "endOffset": 20846,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Sera were stored at -80 \u00b0C to -20 \u00b0C until analysis.",
            "startOffset": 20794,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 28042,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Results were similar by age cohort (Fig. 2).",
            "startOffset": 27998,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 15985,
            "parents": [],
            "secId": "s0005",
            "sentence": "The International Vaccine Institute (IVI, Seoul, Republic of Korea) developed a typhoid conjugate vaccine (Vi-DT) where the Vi polysaccharide (a clinical isolate from India (C6524)) is conjugated to diphtheria toxoid as carrier protein.",
            "startOffset": 15749,
            "title": "Introduction"
        },
        {
            "endOffset": 13553,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 13552,
                    "startOffset": 13547
                },
                "b0015": {
                    "endOffset": 13552,
                    "startOffset": 13547
                }
            },
            "secId": "s0005",
            "sentence": "Symptoms include fever, abdominal pain, and nausea, which last between one to four weeks, and 1\u20132% of hospitalized cases result in death [2,3].",
            "startOffset": 13410,
            "title": "Introduction"
        },
        {
            "endOffset": 24914,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Among 231 subjects screened, 144 participants were enrolled and randomized to either Test or Comparator vaccine groups.",
            "startOffset": 24795,
            "title": "Study population"
        },
        {
            "endOffset": 32751,
            "parents": [],
            "secId": "s0065",
            "sentence": "We measured SBA responses to assess whether typhoid vaccines could induce functional S. Typhi- specific antibodies after vaccination.",
            "startOffset": 32618,
            "title": "Discussion"
        },
        {
            "endOffset": 29943,
            "parents": [],
            "refoffsets": {
                "b0140": {
                    "endOffset": 29942,
                    "startOffset": 29938
                }
            },
            "secId": "s0065",
            "sentence": "DT is known for its safety profile and considered a reliable carrier protein successfully used for meningococcal conjugate vaccines [28].",
            "startOffset": 29806,
            "title": "Discussion"
        },
        {
            "endOffset": 34429,
            "parents": [],
            "secId": "s0065",
            "sentence": "Our results show that Vi-DT is safe and immunogenic in 2\u201345 year old participants and set the stage for further clinical development of Vi-DT in children less than two years of age.",
            "startOffset": 34248,
            "title": "Discussion"
        },
        {
            "endOffset": 30053,
            "parents": [],
            "secId": "s0065",
            "sentence": "Typhoid Vi polysaccharide conjugated to DT as carrier protein was therefore a logical choice for development.",
            "startOffset": 29944,
            "title": "Discussion"
        },
        {
            "endOffset": 18855,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The first and second doses of Test and Comparator vaccines were administered 4 weeks apart.",
            "startOffset": 18764,
            "title": "Vaccines"
        },
        {
            "endOffset": 17647,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Healthy Filipino participants aged 2\u201345 years were enrolled into 3 cohorts of 18\u201345, 6\u201317, and 2\u20135 years in an age de-escalation manner.",
            "startOffset": 17511,
            "title": "Study design and participants"
        },
        {
            "endOffset": 28304,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Geometric Mean Fold rise from baseline to post first dose was 2751.6 decreasing to 2430.3 post second dose.",
            "startOffset": 28197,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 21150,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 21149,
                    "startOffset": 21145
                }
            },
            "secId": "s0030",
            "sentence": "A Vi-reference serum (Vi IgGR1,2011) was used and anti-Vi IgG levels were expressed in \u03bcg/mL [21].",
            "startOffset": 21052,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 20199,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Participants were invited to visit the study site on Days 3, 7 and 28 after each vaccine dose for safety assessment and in case of development of any AE.",
            "startOffset": 20046,
            "title": "Assessment of safety and reactogenicity"
        },
        {
            "endOffset": 23780,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The proportion of participants who experienced solicited and unsolicited AEs after each vaccination was provided with the 95% CI.",
            "startOffset": 23651,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 20644,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Upon SMC recommendation, RITM and IVI IRBs approval were required before proceeding with lower age group enrolment.",
            "startOffset": 20529,
            "title": "Assessment of safety and reactogenicity"
        },
        {
            "endOffset": 30178,
            "parents": [],
            "secId": "s0065",
            "sentence": "We evaluated Vi-DT at the dose of 25 \u00b5g based on dose selection done with various typhoid conjugate vaccines in development.",
            "startOffset": 30054,
            "title": "Discussion"
        },
        {
            "endOffset": 26076,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Irrespective of the age and dose, pain and tenderness were the most common solicited AEs reported in both groups.",
            "startOffset": 25963,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 33089,
            "parents": [],
            "secId": "s0065",
            "sentence": "In addition, a correlation, although weak, was observed between anti-Vi IgG ELISA and SBA titers in all groups combined (Spearman correlation coefficient 0.282, p < 0.0174) (Supplementary Fig. 1).",
            "startOffset": 32893,
            "title": "Discussion"
        },
        {
            "endOffset": 18730,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Both Comparator vaccines were given intramuscularly in the deltoid muscle of the left upper arm for participants aged \u22653 years and in the anterolateral left thigh vastus lateralis muscle for children aged 2\u20133 years.",
            "startOffset": 18515,
            "title": "Vaccines"
        },
        {
            "endOffset": 29045,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "GMF rise post first and second dose was more than 20 times compared to baseline in Test group while there was no rise in Comparator group (Supplementary Table 2).",
            "startOffset": 28883,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 34248,
            "parents": [],
            "refoffsets": {
                "b0180": {
                    "endOffset": 34247,
                    "startOffset": 34243
                }
            },
            "secId": "s0065",
            "sentence": "However, recently, it was shown that bactericidal antibody reduced typhoid severity but not protection against disease in a human challenge model [36].",
            "startOffset": 34097,
            "title": "Discussion"
        },
        {
            "endOffset": 30600,
            "parents": [],
            "secId": "s0065",
            "sentence": "All solicited and unsolicited AEs were mild or moderate in intensity in both vaccine groups with the exception of a 4-year old girl in Test group with grade 3 fever that resolved without sequelae.",
            "startOffset": 30404,
            "title": "Discussion"
        },
        {
            "endOffset": 28882,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Anti-DT responses rate for all age groups were 81.2% and 84.5% post first and second Vi-DT doses, respectively, while 4.4% and 5.6% in Comparator group.",
            "startOffset": 28730,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 20045,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Unsolicited AEs were classified into System Organ Class (SOC) and Preferred Term (PT) using MedDRA (version 18.1, 2015).",
            "startOffset": 19925,
            "title": "Assessment of safety and reactogenicity"
        },
        {
            "endOffset": 21612,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Lower limit of detection for anti-Vi IgG, anti-DT IgG, and SBA is 0.003 \u03bcg/ml (internal qualification, unpublished data), 0.004 IU/ml (manufacturer\u2019s instruction), 10 (reciprocal serum-dilution fold inhibiting 50% of bacterial growth), respectively.",
            "startOffset": 21363,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 25667,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Tenderness was not elicited in young children but was a common immediate reaction in adolescents with 4.2% and 16.7% in Test and Comparator vaccine groups, respectively.",
            "startOffset": 25498,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 25029,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Of those randomized, 68 (94%) in Test and 67 (93%) in Comparator groups completed the study per protocol (Fig. 1).",
            "startOffset": 24915,
            "title": "Study population"
        },
        {
            "endOffset": 30296,
            "parents": [],
            "secId": "s0065",
            "sentence": "In this Phase I study, Vi-DT showed to be safe, well tolerated, and immunogenic in all age cohorts from 2 to 45 years.",
            "startOffset": 30178,
            "title": "Discussion"
        },
        {
            "endOffset": 27490,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Blood creatinine was mildly elevated in 2 participants (2.8%) in Test and 4 (5.6%) in Comparator groups post first dose.",
            "startOffset": 27370,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 15226,
            "parents": [],
            "secId": "s0005",
            "sentence": "These limitations can be overcome by conjugation of the Vi polysaccharide to a carrier protein.",
            "startOffset": 15131,
            "title": "Introduction"
        },
        {
            "endOffset": 24530,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Comparison of Geometric Mean Titer (GMT) of antibody response and 95% CI for all ages was performed using analysis of covariance (ANCOVA) adjusted for age cohort.",
            "startOffset": 24368,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 19924,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Unsolicited Adverse Events were defined as, any other adverse event that occurred from the date of administration of the investigational product (IP) to 28 days following each dose (Days 0\u201328).",
            "startOffset": 19731,
            "title": "Assessment of safety and reactogenicity"
        },
        {
            "endOffset": 16852,
            "parents": [],
            "secId": "s0010",
            "sentence": "Assent was also obtained from 7 to 17 years old children according to the 2011 Philippines National Ethics Guidelines.",
            "startOffset": 16734,
            "title": "Materials and methods"
        },
        {
            "endOffset": 24768,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The primary objective of the study was assessment of safety and the study was not powered to show non-inferiority of immunogenicity between Test and Comparator vaccines.",
            "startOffset": 24599,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 28693,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "SBA GMT were also significantly higher in Test than in Comparator groups post first and second doses (526.6 vs. 271.3, p = 0.016 and 586.5 vs. 223.0, p < 0.001 respectively) (Supplementary Table 1).",
            "startOffset": 28495,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 25497,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Pain at injection site was the most common immediate reaction reported in both groups with 7% and 15.3% in Test and Comparator vaccine groups, respectively.",
            "startOffset": 25341,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 33369,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 33368,
                    "startOffset": 33364
                }
            },
            "secId": "s0065",
            "sentence": "In contrast, natural infection of S. Typhi in an endemic area did not show a correlation between the two types of antibody titers [32].",
            "startOffset": 33234,
            "title": "Discussion"
        },
        {
            "endOffset": 27997,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Test group had about a 4-fold higher anti-Vi IgG ELISA GMT than the Comparator group (p < 0.001) (Table 4).",
            "startOffset": 27890,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 29165,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Overall PP analysis results were in agreement with the immunogenicity set analysis.",
            "startOffset": 29082,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 16399,
            "parents": [],
            "secId": "s0010",
            "sentence": "The clinical study (Clinicaltrials.gov NCT02645032) was approved by the Philippines Food and Drug Administration (PFDA) and the Institutional Review Boards (IRB) of the Research Institute for Tropical Medicine (RITM) and IVI.",
            "startOffset": 16174,
            "title": "Materials and methods"
        },
        {
            "endOffset": 18983,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Participants were assessed for immediate reactions up to 60 min following vaccination.",
            "startOffset": 18897,
            "title": "Assessment of safety and reactogenicity"
        },
        {
            "endOffset": 17510,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This study was conducted at RITM, Manila, the Philippines, from May 2016 to Feb 2017.",
            "startOffset": 17425,
            "title": "Study design and participants"
        },
        {
            "endOffset": 16733,
            "parents": [],
            "secId": "s0010",
            "sentence": "Before any study intervention, a written informed consent was obtained from eligible adult participants and from the parents or legal guardians of participants aged 2\u201317 years.",
            "startOffset": 16557,
            "title": "Materials and methods"
        },
        {
            "endOffset": 23651,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Demographic characteristics of continuous variables were summarized by number of participants, mean, standard deviation, median, minimum and maximum, and categorical variables were summarized by frequency and percentage in each vaccine group.",
            "startOffset": 23409,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 28196,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Test group seroconversion rates were 100% at day 28 post first dose and post second dose, while GMT decreased from 47.4 \u00b5g/mL to 41.4 \u00b5g/mL, respectively.",
            "startOffset": 28042,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 20793,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Blood samples were collected from all trial participants prior to vaccination and 28 days post first and second doses.",
            "startOffset": 20675,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 27711,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "No SAE was reported throughout the study.",
            "startOffset": 27670,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 22225,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Eligible participants in each age cohort were randomly assigned to receive either Vi-DT or Comparator vaccine in a 1:1 ratio.",
            "startOffset": 22100,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 16152,
            "parents": [],
            "secId": "s0005",
            "sentence": "In order to meet the global demand of typhoid conjugate vaccines, IVI has transferred this technology to SK Chemicals, Republic of Korea for future commercialization.",
            "startOffset": 15986,
            "title": "Introduction"
        },
        {
            "endOffset": 15060,
            "parents": [],
            "secId": "s0005",
            "sentence": "Immune responses to bacterial capsular polysaccharides are characterized by T-cell independence, lack of affinity maturation, poor antibody subclass switching and inability to generate memory.",
            "startOffset": 14868,
            "title": "Introduction"
        },
        {
            "endOffset": 28494,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "SBA seroconversion rates were significantly higher in Test than in Comparator groups post first and second doses (71.0% vs. 52.2%, P-value 0.022 and 70.4% vs. 51.4%, p = 0.019, respectively.",
            "startOffset": 28304,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 30353,
            "parents": [],
            "secId": "s0065",
            "sentence": "No SAE was reported in either Test or Comparator groups.",
            "startOffset": 30297,
            "title": "Discussion"
        },
        {
            "endOffset": 26658,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Throughout the study period, unsolicited AEs were reported by 55.6% (95% CI: 44.1, 66.5) and 54.2% (95% CI: 42.7, 65.2) of participants in the Test and Comparator groups, respectively.",
            "startOffset": 26474,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 20280,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Serious adverse events (SAE) were recorded for the entire duration of the study.",
            "startOffset": 20200,
            "title": "Assessment of safety and reactogenicity"
        },
        {
            "endOffset": 19393,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Local reactogenicity events (at the site of injection) included pain, tenderness, erythema/redness, swelling/induration and pruritus after study vaccine administration.",
            "startOffset": 19225,
            "title": "Assessment of safety and reactogenicity"
        },
        {
            "endOffset": 13884,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 13883,
                    "startOffset": 13880
                }
            },
            "secId": "s0005",
            "sentence": "Vaccination may provide a short-to-medium term measure to abate the typhoid burden of disease [2].",
            "startOffset": 13786,
            "title": "Introduction"
        },
        {
            "endOffset": 32241,
            "parents": [],
            "refoffsets": {
                "b0140": {
                    "endOffset": 32240,
                    "startOffset": 32236
                }
            },
            "secId": "s0065",
            "sentence": "In a phase I clinical trial of O-acetylated pectin conjugate typhoid vaccine conducted in young children, and a >4-fold rise of anti-Vi IgG GMT was observed 6 weeks post injection [28].",
            "startOffset": 32056,
            "title": "Discussion"
        },
        {
            "endOffset": 17821,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The primary objective of the study was to evaluate the safety of Vi-DT, while the secondary objectives were to assess the immunogenicity of Vi-DT comparatively to Typhim Vi\u00ae.",
            "startOffset": 17647,
            "title": "Study design and participants"
        },
        {
            "endOffset": 13409,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 13408,
                    "startOffset": 13405
                }
            },
            "secId": "s0005",
            "sentence": "Typhoid fever is one of the most common causes of bacteremia in several low- and middle-income countries (LMIC) and has been estimated to cause 11\u201321 million cases and 145,000\u2013161,000 deaths per year [1].",
            "startOffset": 13205,
            "title": "Introduction"
        },
        {
            "endOffset": 25962,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The proportion of participants reporting solicited AEs within 7 days after any dose of Test or Comparator vaccine was 38.9% (95% CI: 28.5, 50.4) and 40.3% (95% CI: 29.7, 51.8), respectively.",
            "startOffset": 25772,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 34096,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 34095,
                    "startOffset": 34088
                },
                "b0175": {
                    "endOffset": 34095,
                    "startOffset": 34088
                }
            },
            "secId": "s0065",
            "sentence": "Some studies suggest that anti-Vi IgG contributed to reduce disease symptoms and prevention of infection in some individuals [34,35].",
            "startOffset": 33963,
            "title": "Discussion"
        },
        {
            "endOffset": 26789,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "All unsolicited AEs reported were of mild to moderate severity only and most of them were assessed unrelated to vaccine (Table 3).",
            "startOffset": 26659,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 14867,
            "parents": [],
            "secId": "s0005",
            "sentence": "Although Vi polysaccharide vaccination has been shown to protect individuals from typhoid fever, it has several limitations due to T cell-independent properties.",
            "startOffset": 14706,
            "title": "Introduction"
        },
        {
            "endOffset": 21258,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Anti-DT IgG levels were measured by ELISA (Diphtheria IgG ELISA, IBL International GmbH, Hamburg, Germany).",
            "startOffset": 21151,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 26365,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Pain, tenderness and headache were the most common solicited AEs reported among adults in both groups.",
            "startOffset": 26263,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 30719,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 30718,
                    "startOffset": 30702
                },
                "b0115": {
                    "endOffset": 30718,
                    "startOffset": 30702
                },
                "b0125": {
                    "endOffset": 30718,
                    "startOffset": 30702
                },
                "b0135": {
                    "endOffset": 30718,
                    "startOffset": 30702
                },
                "b0145": {
                    "endOffset": 30718,
                    "startOffset": 30702
                }
            },
            "secId": "s0065",
            "sentence": "The overall Vi-DT safety profile is in line with those of other Vi polysaccharide conjugate vaccines [21,23,25,27,29].",
            "startOffset": 30601,
            "title": "Discussion"
        },
        {
            "endOffset": 32892,
            "parents": [],
            "secId": "s0065",
            "sentence": "SBA titers showed significantly higher GMT in Test vs. Comparator groups, consistent with anti-Vi IgG ELISA results (Supplementary Table 1).",
            "startOffset": 32752,
            "title": "Discussion"
        },
        {
            "endOffset": 19730,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Solicited systemic AEs included fever, headache, fatigue, arthralgia, myalgia, chills, nausea/vomiting and acute allergic reaction after study vaccine administration.",
            "startOffset": 19564,
            "title": "Assessment of safety and reactogenicity"
        },
        {
            "endOffset": 33962,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 33767,
                    "startOffset": 33763
                }
            },
            "secId": "s0065",
            "sentence": "Given the fact that antibody responses to LPS were reported in the Vi polysaccharide vaccination group [33] and depletion of LPS-specific antibody in serum significantly reduced SBA activity, residual LPS of S. Typhi in both Vi and Vi-DT vaccines may induce SBA response in both Vi and Vi-DT vaccinees.",
            "startOffset": 33660,
            "title": "Discussion"
        },
        {
            "endOffset": 26939,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "In all age cohorts within 28 days post first dose, 10 participants (13.9%) in Test and 6 (8.3%) in Comparator groups had acute respiratory infections.",
            "startOffset": 26789,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 28730,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Results were similar per age cohort.",
            "startOffset": 28694,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 19563,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Tenderness was sought in adults and adolescents only.",
            "startOffset": 19510,
            "title": "Assessment of safety and reactogenicity"
        },
        {
            "endOffset": 27161,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Within 28 days post second dose, 10 participants (14.7%) in Test and 12 (17.7%) in Comparator groups had acute respiratory infections.",
            "startOffset": 27027,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 31717,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 31716,
                    "startOffset": 31712
                }
            },
            "secId": "s0065",
            "sentence": "In adults, PedaTyph was significantly more immunogenic than Vi alone [16].",
            "startOffset": 31643,
            "title": "Discussion"
        },
        {
            "endOffset": 22342,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Three randomization lists, one for each age cohort were generated by a statistician independent of the study at IVI.",
            "startOffset": 22226,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 27889,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "As per immunogenicity set analysis all participants in Test group (100%) showed seroconversion post first and second doses vs 97% in Comparator group.",
            "startOffset": 27739,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 30939,
            "parents": [],
            "secId": "s0065",
            "sentence": "All participants in Test group (100%) showed seroconversion, i.e., 4-fold rise in serum anti-Vi IgG ELISA after first and second doses while the proportion in the Comparator group was 97% post first dose and second dose.",
            "startOffset": 30719,
            "title": "Discussion"
        },
        {
            "endOffset": 15130,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 15129,
                    "startOffset": 15122
                },
                "b0070": {
                    "endOffset": 15129,
                    "startOffset": 15122
                }
            },
            "secId": "s0005",
            "sentence": "This limits their use in children less than two years of age [13,14].",
            "startOffset": 15061,
            "title": "Introduction"
        },
        {
            "endOffset": 25340,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "All age cohorts were comparable for immediate reactions in both groups and reactions were mild.",
            "startOffset": 25245,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 14705,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 14704,
                    "startOffset": 14697
                },
                "b0060": {
                    "endOffset": 14704,
                    "startOffset": 14697
                }
            },
            "secId": "s0005",
            "sentence": "The single-dose injectable Vi polysaccharide vaccine provides similar levels of protection for at least 3 years and is licensed from 2 years of age [11,12].",
            "startOffset": 14549,
            "title": "Introduction"
        },
        {
            "endOffset": 20386,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 20385,
                    "startOffset": 20381
                }
            },
            "secId": "s0025",
            "sentence": "Abnormal lab values (hematology and biochemistry) were graded using NIAID toxicity grading criteria [20].",
            "startOffset": 20281,
            "title": "Assessment of safety and reactogenicity"
        },
        {
            "endOffset": 14151,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 14150,
                    "startOffset": 14147
                }
            },
            "secId": "s0005",
            "sentence": "It is therefore essential to consider a comprehensive approach that combines targeted vaccination of at-risk populations as a short- to medium-term prevention measure, along with longer term solutions of improvements of water and sanitation and living standards [7].",
            "startOffset": 13885,
            "title": "Introduction"
        },
        {
            "endOffset": 26474,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Pain-tenderness and pain-fever were the most common solicited AEs in adolescents and children, respectively.",
            "startOffset": 26366,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 27369,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Five participants (6.9%) in both Test and Comparator groups had elevated liver enzymes post first dose, all asymptomatic.",
            "startOffset": 27248,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 27026,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Fever was reported by 3 participants (4.2%) in Test and 1 (1.4%) in Comparator groups.",
            "startOffset": 26940,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 33659,
            "parents": [],
            "secId": "s0065",
            "sentence": "Vi-DT contains a small amount of endotoxin (9.65 EU/dose, provided by manufacturer) which is within acceptable range for human vaccines.",
            "startOffset": 33523,
            "title": "Discussion"
        },
        {
            "endOffset": 14260,
            "parents": [],
            "secId": "s0005",
            "sentence": "Several safe and effective typhoid vaccines that could help reduce disease burden are licensed and available.",
            "startOffset": 14151,
            "title": "Introduction"
        },
        {
            "endOffset": 18514,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Since the Comparator vaccine is administered as a single dose, the second dose administered was a flu vaccine (Vaxigrip\u00ae, split viron, inactivated influenza vaccine, southern hemisphere, Sanofi Pasteur) to keep the blinding.",
            "startOffset": 18290,
            "title": "Vaccines"
        },
        {
            "endOffset": 22100,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Since the primary endpoint is safety, the overall study sample size was calculated so that for each vaccine and age cohort, with 24 participants per vaccine and age group, there is a 90% probability of observing at least one participant with an adverse event if the true rate of such an event is 10%.",
            "startOffset": 21800,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 15558,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 15557,
                    "startOffset": 15553
                }
            },
            "secId": "s0005",
            "sentence": "Two Vi polysaccharide vaccines conjugated to tetanus toxoid as carrier protein are licensed in India for use from 3 to 6 months of age [16].",
            "startOffset": 15418,
            "title": "Introduction"
        },
        {
            "endOffset": 30403,
            "parents": [],
            "secId": "s0065",
            "sentence": "No participant withdrew from the study due to AE.",
            "startOffset": 30354,
            "title": "Discussion"
        },
        {
            "endOffset": 22872,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The immunogenicity analysis was performed in immunogenicity and per-protocol (PP) sets.",
            "startOffset": 22785,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 15417,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 15416,
                    "startOffset": 15412
                }
            },
            "secId": "s0005",
            "sentence": "Conjugation of the polysaccharide to a carrier protein converts the immune response to T-cell dependent characterized by affinity maturation, subclass switching and induction of memory [15].",
            "startOffset": 15227,
            "title": "Introduction"
        },
        {
            "endOffset": 27564,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Elevated lab values returned to normal in subsequent follow-up lab tests.",
            "startOffset": 27491,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 26262,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "All AEs reported were of mild to moderate severity in all age cohorts from both vaccine groups except a 4-year old girl with grade 3 fever in Test group which resolved without sequelae.",
            "startOffset": 26077,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 31642,
            "parents": [],
            "secId": "s0065",
            "sentence": "PedaTyph elicited similar levels of anti-Vi IgG in infants and older children (2- to 5-year-old).",
            "startOffset": 31545,
            "title": "Discussion"
        },
        {
            "endOffset": 21362,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0110": {
                    "endOffset": 21361,
                    "startOffset": 21357
                }
            },
            "secId": "s0030",
            "sentence": "Serum bactericidal assay (SBA) was performed using a semi-automated assay as previously described [22].",
            "startOffset": 21259,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 23409,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The PP analysis set was a subset of the intention-to treat population with no emergent deviation (defined as major deviation from the protocol compromising the safety of the participants and/or the scientific integrity of the protocol), compliance to study procedures, completion of all scheduled visits, and administration of the correct vaccinations.",
            "startOffset": 23057,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 29805,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 29804,
                    "startOffset": 29800
                }
            },
            "secId": "s0065",
            "sentence": "Dose-finding studies with Vi-rEPA, using 3 dose levels of 5, 12.5, and 25 \u00b5g revealed a dose-dependent increase in anti-Vi IgG responses, with 25 \u00b5g eliciting the highest anti-Vi IgG titers [27].",
            "startOffset": 29610,
            "title": "Discussion"
        },
        {
            "endOffset": 19224,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Participants/parents/guardians were provided with a thermometer and diary cards (DC) to record axillary temperature and any adverse event (AE) daily up to 7 days after each dose for solicited or up to 28 days for unsolicited adverse events.",
            "startOffset": 18984,
            "title": "Assessment of safety and reactogenicity"
        },
        {
            "endOffset": 31222,
            "parents": [],
            "secId": "s0065",
            "sentence": "No further increase of GMT was detected post second dose of Vi-DT compared to post first dose, which suggests a single dose may be sufficient to achieve the same level of immune response in 2\u201345 year age group.",
            "startOffset": 31012,
            "title": "Discussion"
        },
        {
            "endOffset": 17940,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The Test vaccine (Vi-DT) used in this study is a purified Vi polysaccharide conjugated to diphtheria toxoid.",
            "startOffset": 17832,
            "title": "Vaccines"
        },
        {
            "endOffset": 21051,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 20917,
                    "startOffset": 20913
                }
            },
            "secId": "s0030",
            "sentence": "Anti-Vi IgG in sera were measured by ELISA as previously described [21] with the exception of added pre-coating of poly-L-lysine (1 \u03bcg/well) (Sigma, USA) prior to Vi coating (0.2 \u03bcg/well) onto microplates.",
            "startOffset": 20846,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 25244,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "A total of 22 participants reported immediate reactions in both Test and Comparator groups combined.",
            "startOffset": 25144,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 29609,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 29608,
                    "startOffset": 29601
                },
                "b0125": {
                    "endOffset": 29608,
                    "startOffset": 29601
                },
                "b0130": {
                    "endOffset": 29608,
                    "startOffset": 29601
                }
            },
            "secId": "s0065",
            "sentence": "Carrier proteins such as recombinant exoprotein A from Pseudomonas aeruginosa (rEPA), Tetanus toxoid (TT), Diphtheria toxoid (DT) or a non-toxic mutant of diphtheria toxin (CRM 197) have been used with success for Vi polysaccharide conjugate vaccines [24\u201326].",
            "startOffset": 29350,
            "title": "Discussion"
        },
        {
            "endOffset": 31340,
            "parents": [],
            "secId": "s0065",
            "sentence": "The results from this study are in agreement with other studies of typhoid conjugate vaccines in similar age cohorts.",
            "startOffset": 31223,
            "title": "Discussion"
        },
        {
            "endOffset": 29349,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 29348,
                    "startOffset": 29344
                }
            },
            "secId": "s0065",
            "sentence": "Conjugation to a carrier protein converts T cell-independent antigens into T cell-dependent ones, thereby, providing a long lasting immune response by enhancing memory [23].",
            "startOffset": 29176,
            "title": "Discussion"
        },
        {
            "endOffset": 15749,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 15670,
                    "startOffset": 15666
                },
                "b0090": {
                    "endOffset": 15748,
                    "startOffset": 15741
                },
                "b0095": {
                    "endOffset": 15748,
                    "startOffset": 15741
                }
            },
            "secId": "s0005",
            "sentence": "The immunogenicity of typhoid conjugate vaccines in children under 2 years of age is an important advance, [17] given the significant burden of disease in young children and infants [18,19].",
            "startOffset": 15559,
            "title": "Introduction"
        },
        {
            "endOffset": 17141,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This was a randomized, observer-blinded, Phase I study to assess the safety and immunogenicity of 25 \u00b5g Vi-DT typhoid conjugate vaccine (Test vaccine) compared with Vi polysaccharide typhoid vaccine (25 \u00b5g) (Typhim Vi\u00ae, Sanofi Pasteur) (Comparator vaccine).",
            "startOffset": 16884,
            "title": "Study design and participants"
        },
        {
            "endOffset": 27670,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "All participants were asymptomatic and abnormal lab values were assessed as \u2018not clinically significant\u2019.",
            "startOffset": 27565,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 18289,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The Comparator vaccine Typhim Vi\u00ae (Sanofi Pasteur) contained 25 \u00b5g of purified Vi polysaccharide (S. Typhi Ty2).",
            "startOffset": 18177,
            "title": "Vaccines"
        },
        {
            "endOffset": 16556,
            "parents": [],
            "secId": "s0010",
            "sentence": "The study was conducted in accordance with the ICH E8 Guidelines for Good Clinical Practice (GCP) and the ethical principles of the Declaration of Helsinki.",
            "startOffset": 16400,
            "title": "Materials and methods"
        },
        {
            "endOffset": 21777,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "For statistical analysis, antibody levels including anti-Vi IgG, anti-DT IgG, and SBA titers below level of detection were assigned as half of the detectable value.",
            "startOffset": 21613,
            "title": "Assessment of immunogenicity"
        },
        {
            "endOffset": 32617,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 32616,
                    "startOffset": 32609
                },
                "b0155": {
                    "endOffset": 32616,
                    "startOffset": 32609
                }
            },
            "secId": "s0065",
            "sentence": "Serum bactericidal assays have been widely used to assess immunogenicity of bacterial vaccines such as cholera and meningococcal vaccines due to its correlation with protection [30,31].",
            "startOffset": 32432,
            "title": "Discussion"
        },
        {
            "endOffset": 19509,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Tenderness as a solicited reaction was not sought in children as it is difficult to assess in younger participants.",
            "startOffset": 19394,
            "title": "Assessment of safety and reactogenicity"
        },
        {
            "endOffset": 18176,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The vaccine containing two active ingredients, 25 \u00b5g of purified Vi polysaccharide (S. Typhi C6524) and diphtheria toxoid (Corynebacterium diphtheria PW No.8) formulated with stabilizers was administered intramuscularly as 0.5 mL/vial.",
            "startOffset": 17941,
            "title": "Vaccines"
        },
        {
            "endOffset": 22551,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Block randomization was employed to ensure an effective balance between interventions within each age cohort.",
            "startOffset": 22442,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 29082,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Results were similar per age cohort.",
            "startOffset": 29046,
            "title": "Immunogenicity evaluation"
        },
        {
            "endOffset": 25771,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Table 2 provides the proportion of participants with solicited AEs per vaccine group, all ages combined.",
            "startOffset": 25667,
            "title": "Safety evaluation"
        },
        {
            "endOffset": 25124,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Both groups were comparable with regard to demographic and baseline characteristics (Table 1).",
            "startOffset": 25030,
            "title": "Study population"
        },
        {
            "endOffset": 14548,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 14547,
                    "startOffset": 14541
                },
                "b0045": {
                    "endOffset": 14547,
                    "startOffset": 14541
                },
                "b0050": {
                    "endOffset": 14547,
                    "startOffset": 14541
                }
            },
            "secId": "s0005",
            "sentence": "Three or four doses of orally administered live-attenuated Ty21a provide about 50\u201370% protection for at least 7 years and is licensed in capsule form from 5 years of age or as a liquid formulation from 2 years of age, although the liquid formulation is not commercially available [8-10].",
            "startOffset": 14261,
            "title": "Introduction"
        },
        {
            "endOffset": 23056,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The immunogenicity set was defined as participants who were randomized, received at least one dose of study vaccine and provided at least one post baseline measure for immunogenicity.",
            "startOffset": 22873,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 17424,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Since Test and Comparator vaccines differ in their presentation, the study was observer-blinded (safety evaluators and other trial staff remained blinded with the exception of the vaccine administrator) to ensure evaluator\u2019s blinding to prevent bias in assessment of adverse events.",
            "startOffset": 17142,
            "title": "Study design and participants"
        },
        {
            "endOffset": 22654,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "All randomized participants were included in the analysis of demographics and baseline characteristics.",
            "startOffset": 22551,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 24598,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "All analyses were performed using SAS 9.4 (SAS Institute, Cary NC).",
            "startOffset": 24531,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 32055,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 32054,
                    "startOffset": 32050
                }
            },
            "secId": "s0065",
            "sentence": "Typbar-TCV from Bharat biotech was administered as single dose vs. polysaccharide vaccine (Typbar) in children 2\u20134 and 5\u201315 years of age, where the conjugate vaccine was significantly more immunogenic, with a 152- and 168-fold rise in GMT at day 42 over baseline, compared to a 46- and 37-fold rise elicited by Typbar, respectively [29].",
            "startOffset": 31718,
            "title": "Discussion"
        },
        {
            "endOffset": 33522,
            "parents": [],
            "secId": "s0065",
            "sentence": "One possible explanation is that predominant antibody responses are directed to other bacterial components such as LPS or membrane proteins in patients.",
            "startOffset": 33370,
            "title": "Discussion"
        },
        {
            "endOffset": 13785,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 13784,
                    "startOffset": 13779
                },
                "b0025": {
                    "endOffset": 13687,
                    "startOffset": 13682
                },
                "b0030": {
                    "endOffset": 13784,
                    "startOffset": 13779
                }
            },
            "secId": "s0005",
            "sentence": "Improved sanitation contributed to the sharp decline of typhoid fever in industrialized countries during the early 20th century [4,5] but such infrastructure is slow to materialize in places where the disease remains endemic [4,6].",
            "startOffset": 13554,
            "title": "Introduction"
        },
        {
            "endOffset": 22784,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "In the safety analysis set, safety was analyzed for all randomized participants who received at least one dose of study vaccines.",
            "startOffset": 22655,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 31544,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 31543,
                    "startOffset": 31539
                }
            },
            "secId": "s0065",
            "sentence": "One of the studies that tested PedaTyph Vi-TT conjugate vaccine reported 1.8 EU/mL (95% Cl 1.5, 2 EU/mL) as baseline GMT which increased to 32 EU/mL (95% Cl 27, 39 EU/mL) at 6-weeks post first dose [23].",
            "startOffset": 31341,
            "title": "Discussion"
        },
        {
            "endOffset": 33233,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 33149,
                    "startOffset": 33145
                },
                "b0160": {
                    "endOffset": 33232,
                    "startOffset": 33228
                }
            },
            "secId": "s0065",
            "sentence": "A similar correlation was observed in a previous study [22] and SBA titers were inversely correlated with susceptibility to typhoid fever [32].",
            "startOffset": 33090,
            "title": "Discussion"
        },
        {
            "endOffset": 18763,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Vaccines were stored at +2\u20138 \u00b0C.",
            "startOffset": 18731,
            "title": "Vaccines"
        },
        {
            "endOffset": 24367,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The proportion of participants with seroconversion (defined as fourfold rise in anti-Vi antibody titers compared to baseline), 4 weeks post first and second doses of Vi-DT and post one dose of Vi polysaccharide vaccine was provided and comparison was performed by stratified Chi-square test (Cochran-Mantel-Haenszel test) for overall age group.",
            "startOffset": 24023,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 27248,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Fever was reported by 4 participants (5.9%) in Test and 2 (2.9%) in Comparator groups.",
            "startOffset": 27162,
            "title": "Safety evaluation"
        }
    ],
    "docId": "S0264410X18306583",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": null,
                "first": "Maria Rosario",
                "initial": "M.R.",
                "last": "Capeding"
            },
            {
                "email": null,
                "first": "Samuel",
                "initial": "S.",
                "last": "Teshome"
            },
            {
                "email": "Tarun.Saluja@ivi.int",
                "first": "Tarun",
                "initial": "T.",
                "last": "Saluja"
            },
            {
                "email": null,
                "first": "Khalid Ali",
                "initial": "K.A.",
                "last": "Syed"
            },
            {
                "email": null,
                "first": "Deok Ryun",
                "initial": "D.R.",
                "last": "Kim"
            },
            {
                "email": null,
                "first": "Ju Yeon",
                "initial": "J.Y.",
                "last": "Park"
            },
            {
                "email": null,
                "first": "Jae Seung",
                "initial": "J.S.",
                "last": "Yang"
            },
            {
                "email": null,
                "first": "Yang Hee",
                "initial": "Y.H.",
                "last": "Kim"
            },
            {
                "email": null,
                "first": "Jiwook",
                "initial": "J.",
                "last": "Park"
            },
            {
                "email": null,
                "first": "Sue Kyoung",
                "initial": "S.K.",
                "last": "Jo"
            },
            {
                "email": null,
                "first": "Yun",
                "initial": "Y.",
                "last": "Chon"
            },
            {
                "email": null,
                "first": "Sudeep",
                "initial": "S.",
                "last": "Kothari"
            },
            {
                "email": null,
                "first": "Seon Young",
                "initial": "S.Y.",
                "last": "Yang"
            },
            {
                "email": null,
                "first": "Dong Soo",
                "initial": "D.S.",
                "last": "Ham"
            },
            {
                "email": null,
                "first": "Ji Hwa",
                "initial": "J.H.",
                "last": "Ryu"
            },
            {
                "email": null,
                "first": "Hee Seong",
                "initial": "H.S.",
                "last": "Hwang"
            },
            {
                "email": null,
                "first": "Ju Hwan",
                "initial": "J.H.",
                "last": "Mun"
            },
            {
                "email": null,
                "first": "Julia A.",
                "initial": "J.A.",
                "last": "Lynch"
            },
            {
                "email": null,
                "first": "Jerome H.",
                "initial": "J.H.",
                "last": "Kim"
            },
            {
                "email": null,
                "first": "Hun",
                "initial": "H.",
                "last": "Kim"
            },
            {
                "email": null,
                "first": "Jean Louis",
                "initial": "J.L.",
                "last": "Excler"
            },
            {
                "email": null,
                "first": "Sushant",
                "initial": "S.",
                "last": "Sahastrabuddhe"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.05.038",
        "firstpage": "3794",
        "issn": "0264410X",
        "keywords": [
            "Conjugate vaccine",
            "Immunogenicity",
            "Safety",
            "The Philippines",
            "Typhoid",
            "Vi-DT"
        ],
        "lastpage": "3801",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children"
    }
}